Pirfenidone (Esbriet) is an oral antifibrotic medication used for the treatment of idiopathic pulmonary fibrosis (IPF). It slows down disease progression by inhibiting the fibrotic process.

How Effective is Pirfenidone (Esbriet) in Treatment?

Improvement in Lung Function

Studies have shown that pirfenidone can effectively slow down the rate of decline in lung function (such as forced vital capacity, FVC) in IPF patients, and the stable period of the disease is prolonged in some patients.

Its effect remains stable during long-term treatment, and no significant attenuation of efficacy has been observed.

Delay of Disease Progression

Pirfenidone can reduce the risk of acute exacerbations and the need for hospitalization due to disease deterioration, thereby improving patients' quality of life.

Some patients report relief from symptoms such as cough and dyspnea.

Characteristics of Efficacy

Common adverse reactions include gastrointestinal reactions (e.g., nausea, diarrhea), photosensitive rash, and abnormal liver function. Most of these reactions are mild to moderate and can be alleviated through dosage adjustment or symptomatic treatment.

Severe liver damage or persistent gastrointestinal symptoms require discontinuation of the medication.

Indicated Populations for Pirfenidone (Esbriet)

Target Patient Populations

Adult patients diagnosed with IPF: Diagnosis must be confirmed by high-resolution computed tomography (HRCT) or lung biopsy.

Patients with mild to moderate hepatic/renal impairment: Dosage adjustment and close monitoring are required (e.g., Child-Pugh Class A/B or mild to moderate renal impairment).

Elderly patients: No dosage adjustment is needed, but assessment of concurrent medications and fall risk is required.

Absolute Contraindications

Patients with severe hepatic impairment (Child-Pugh Class C) or end-stage renal disease requiring dialysis.

Patients allergic to pirfenidone or any of its components.

Relative Precautions for Use

Smokers: Smoking may reduce drug exposure, so smoking cessation is required.

Concurrent use of strong CYP1A2 inhibitors (e.g., fluvoxamine) or inducers (e.g., rifampicin).

Medication Monitoring for Pirfenidone (Esbriet)

Pre-Treatment Assessment

Baseline examinations: Liver function (ALT/AST/bilirubin), renal function (creatinine clearance), and lung function (FVC/DLCO).

Drug screening: Avoid concurrent use of strong CYP1A2 inhibitors (discontinuation or dosage adjustment is required if concurrent use is necessary).

Monitoring During Treatment

Liver function: Test monthly for the first 6 months, then recheck every 3 months; if ALT/AST exceeds 3 times the normal value, dosage reduction or discontinuation is required.

Photosensitive reactions: Avoid sun exposure, use sunscreen with SPF 50+, and assess whether dosage reduction is needed if a rash occurs.

Gastrointestinal symptoms: It is recommended to take the medication with meals; if persistent vomiting or diarrhea occurs, dosage adjustment is required.

Key Points for Patient Education

Dose titration: Gradually increase the dose to the maintenance dose (3 capsules per dose, 3 times a day) within the initial 2 weeks. If a dose is missed for more than 14 days, re-titration is required.

Lifestyle: Quit smoking, avoid alcohol and photosensitive medications (e.g., tetracyclines).